DCM
ROIV icon

DME Capital Management’s Roivant Sciences ROIV Stock Holding History

DME Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.6M Buy
2,152,669
+83,360
+4% +$2.14M 1.87% 18
2025
Q4 		$44.9M Sell
2,069,309
-206,220
-9% -$4.07M 1.58% 19
2025
Q3 		$34.4M Sell
2,275,529
-2,275,528
-50% -$28.2M 1.35% 20
2025
Q2 		$51.3M Sell
4,551,057
-890,110
-16% -$9.65M 2.21% 16
2025
Q1 		$54.9M Buy
5,441,167
+170,100
+3% +$1.84M 2.78% 12
2024
Q4 		$62.4M Sell
5,271,067
-36,973
-0.7% -$437K 3.21% 10
2024
Q3 		$61.3M Buy
5,308,040
+497,080
+10% +$5.66M 2.55% 11
2024
Q2 		$50.9M Buy
4,810,960
+620,470
+15% +$6.8M 2.49% 12
2024
Q1 		$44.2M Buy
+4,190,490
New +$45.2M 2.02% 16

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DME Capital Management's ROIV Position: Q1 2026 in Review

DME Capital Management increased its Roivant Sciences (ROIV) stake by 4% in Q1 2026, buying an estimated $2.14M and bringing the position to 2,152,669 shares worth $59.6M. The position accounts for 1.87% of the portfolio, ranked #18.

DME Capital Management first reported a position in ROIV in Q1 2024 and has held it in 9 quarters since. The position peaked at $62.4M in Q4 2024. 441 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • DME Capital Management held 2,152,669 shares of Roivant Sciences worth $59.6M as of Q1 2026.
  • DME Capital Management bought 83,360 Roivant Sciences shares in Q1 2026, an estimated $2.14M.
  • Roivant Sciences made up 1.87% of DME Capital Management's portfolio in Q1 2026, its #18 holding.
  • DME Capital Management first reported a position in Roivant Sciences in Q1 2024 and has held it in 9 quarters since.
  • DME Capital Management's Roivant Sciences position peaked at $62.4M in Q4 2024.
  • 441 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.